JAK Inhibitors in Alopecia Areata: How to Use in Varied Clinical Scenarios
Podcast 1: JAK Inhibitors in Alopecia Areata: What Non-Dermatologists Need to Know
Post-Test/Evaluation
Questions marked with a
*
are required
100%
Contact Information
First Name
Last Name
Email Address
Credentials/Degree (MD, DO, RN, etc.)
Date of Participation
Month
Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
Day
01
02
03
04
05
06
07
08
09
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
Year
2018
2019
2020
2021
2022
2023
2024
2025
A 25-year-old man with a 2-year history of severe alopecia areata (AA) effecting the scalp, eyebrows, eyelashes, and beard presents to your office seeking treatment. The patient is currently treating his AA with combination oral minoxidil, topical minoxidil 5% foam, and topical steroids; but has failed to achieve an adequate response after 8 months. He currently has approximately 80% scalp hair loss, complete eyelash loss, and patchy hair loss in his beard and eyebrows. What treatment would you recommend next for this patient?
Continue on current treatment regimen through 12 months and reevaluate
Add baricitinib
Add topical ruxolitinib
Add pulsed corticosteroids
None of the above
In which of the following scenarios are patients most likely to respond to JAK inhibitor therapy for alopecia areata?
If they have failed other therapies
If they have complete scalp hair loss
If the duration of their current episode of hair loss is less than 4 years
Predictors of therapy success are not yet known
What is your job role?
Dermatologist (Hair and Scalp Disorders)
Dermatologist (General)
Internist
Primary Care Physician
Physician Assistant
Nurse Practitioner
Other
What is your type of practice?
Community/Private
Academic
Hospital
HMO/MCO
Other
How many years have you been in practice?
Fewer than 5
5 to 9
10 to 15
More than 15
N/A
Please estimate the number of patients with alopecia areata you provide for weekly:
1-10
11-25
26-50
51-75
76-100
101-125
> 125
N/A
Were the following learning objectives met?
Please check appropriate rating:
Strongly Agree
Agree
Neutral
Disagree
Strongly Disagree
Determine which patients with alopecia areata would benefit from treatment with Janus Kinase (JAK) inhibitors based on patient and disease characteristics
Strongly Agree
Agree
Neutral
Disagree
Strongly Disagree
Please rate your confidence in your ability to diagnose, treat, and manage alopecia areata on a scale of 1 to 5, where 1 means "not confident at all" and 5 means "very confident."
Confidence
1
2
3
4
5
As a result of this course, I will likely make changes to my practice.
Yes
No
N/A
In particular, as a result of this course, I will be more likely to implement the following changes:
(Please check all that apply)
More frequently consider factors beyond hair loss when selecting treatment strategies for patients with alopecia areata
Incorporate safety and efficacy data on JAK inhibitors into individualized treatment strategies for patients with severe alopecia areata
Implement patient counseling and education to address the psychosocial burden of alopecia areata
Additionally, I will change:
What barriers may prevent/inhibit changes in practice recommended in this activity?
(Please check all that apply)
Cost
Time
# of Patients
Access/Availability
Patient Understanding
Compliance
Other
Did you like the activity format?
Yes
No
If YES, how do you feel it impacted your learning?
(Please check all that apply)
:
Improved understanding of how to speak with patients about the topic of alopecia areata
Increased knowledge of validated tools to assess alopecia areata and how to use them in practice
Will improve recall of material presented
Will improve dialogue with patients
Please evaluate this activity as a whole.
Strongly agree
Agree
Neutral
Disagree
Strongly disagree
The learning format was interactive and engaging
Strongly agree
Agree
Neutral
Disagree
Strongly disagree
The content was pertinent to my professional needs
Strongly agree
Agree
Neutral
Disagree
Strongly disagree
The activity will ultimately benefit patient care
Strongly agree
Agree
Neutral
Disagree
Strongly disagree
I would recommend this activity to colleagues
Strongly agree
Agree
Neutral
Disagree
Strongly disagree
Do you feel a commercial product, device, or service was inappropriately promoted in this educational activity?
Yes
No
What was the most effective aspect(s) of this learning activity?
(Please check all that apply)
Faculty expertise
Educational format
Visual Aids
Content
Case Studies
Other
Do you have suggestions for improving the session or topics for future activities?
(Please check all that apply)
New and Emerging Therapies
Diagnostic Tools/Techniques
Patient Education/Communication
Other Treatment Modalities
Coordination of Care
Other
Please evaluate the faculty: Amy McMichael, MD
Poor
Fair
Average
Good
Excellent
Med Learning Group has my permission to fax or email information to me about further programs.
Yes
No
At times, MLG partners to conduct educational outcomes analyses on treatment and/or diagnosis behavior that are all deidentified and rolled-up across all learners.
I give permission to use my deidentified outcomes data for further research related to the impact of CME
I decline the use of my deidentified outcomes data for further research related to the impact of CME
Any additional comments are welcome below.
Done
Powered by
QuestionPro
Loading...
close
drag_indicator
close
Yes
Cancel
Continue
Answer Question
Continue Without Answering
Keep Data
Discard
close